Selected research
Industry Growth & Trends
Global mRNA Vaccine Drugs Development Services Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global mRNA Vaccine Drugs Development Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the mRNA Vaccine Drugs Development Services market include ReciBioPharm, Merck, Samsung Biologics, Thermo Fisher Scientific, Lonza, Ricoh Group, Aldevron, Wuxi Biologics and Genscript Probio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global mRNA Vaccine Drugs Development Services market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The mRNA Vaccine Drugs Development Services market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global mRNA Vaccine Drugs Development Services market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to mRNA Vaccine Drugs Development Services.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global mRNA Vaccine Drugs Development Services market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
mRNA Vaccine Drugs Development Services Market by Company
ReciBioPharm
Merck
Samsung Biologics
Thermo Fisher Scientific
Lonza
Ricoh Group
Aldevron
Wuxi Biologics
Genscript Probio
Novoprotein
Porton Advanced Solutions
Precision NanoSystems
mRNA Vaccine Drugs Development Services Segment by Type
mRNA Process Development Services
mRNA Synthesis Services
mRNA Drug Substance Purification Services
Others
mRNA Vaccine Drugs Development Services Segment by Application
Non-Replicating mRNA Vaccine Drugs
Self-Amplifying mRNA Vaccine Drugs
mRNA Vaccine Drugs Development Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccine Drugs Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccine Drugs Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccine Drugs Development Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of mRNA Vaccine Drugs Development Services companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA Process Development Services
- mRNA Synthesis Services
- mRNA Drug Substance Purification Services
- Others
Applications
- Non-Replicating mRNA Vaccine Drugs
- Self-Amplifying mRNA Vaccine Drugs
Companies covered
- ReciBioPharm
- Merck
- Samsung Biologics
- Thermo Fisher Scientific
- Lonza
- Ricoh Group
- Aldevron
- Wuxi Biologics
- Genscript Probio
- Novoprotein
- Porton Advanced Solutions
- Precision NanoSystems
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global mRNA Vaccine Drugs Development Services Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global mRNA Vaccine Drugs Development Services Market Size by Region (2021-2032)
- 1.4.1 Global mRNA Vaccine Drugs Development Services Market Size by Region (2021-2026)
- 1.4.2 Global mRNA Vaccine Drugs Development Services Market Size by Region (2027-2032)
- 1.5 Key Regions mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 1.5.1 North America mRNA Vaccine Drugs Development Services Market Size Growth Rate (2021-2032)
- 1.5.2 Europe mRNA Vaccine Drugs Development Services Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size Growth Rate (2021-2032)
- 1.5.4 South America mRNA Vaccine Drugs Development Services Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa mRNA Vaccine Drugs Development Services Market Size Growth Rate (2021-2032)
2 mRNA Vaccine Drugs Development Services Market by Type
- 2.1 Type Introduction
- 2.1.1 mRNA Process Development Services
- 2.1.2 mRNA Synthesis Services
- 2.1.3 mRNA Drug Substance Purification Services
- 2.1.4 Others
- 2.2 Global mRNA Vaccine Drugs Development Services Market Size by Type
- 2.2.1 Global mRNA Vaccine Drugs Development Services Market Size Overview by Type (2021-2032)
- 2.2.2 Global mRNA Vaccine Drugs Development Services Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global mRNA Vaccine Drugs Development Services Market Size Forecasted by Type (2027-2032)
- 2.3 Global mRNA Vaccine Drugs Development Services Market Size by Regions
- 2.3.1 North America mRNA Vaccine Drugs Development Services Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe mRNA Vaccine Drugs Development Services Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America mRNA Vaccine Drugs Development Services Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa mRNA Vaccine Drugs Development Services Market Size Breakdown by Type (2021-2026)
3 mRNA Vaccine Drugs Development Services Market by Application
- 3.1 Type Introduction
- 3.1.1 Non-Replicating mRNA Vaccine Drugs
- 3.1.2 Self-Amplifying mRNA Vaccine Drugs
- 3.2 Global mRNA Vaccine Drugs Development Services Market Size by Application
- 3.2.1 Global mRNA Vaccine Drugs Development Services Market Size Overview by Application (2021-2032)
- 3.2.2 Global mRNA Vaccine Drugs Development Services Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global mRNA Vaccine Drugs Development Services Market Size Forecasted by Application (2027-2032)
- 3.3 Global mRNA Vaccine Drugs Development Services Market Size by Regions
- 3.3.1 North America mRNA Vaccine Drugs Development Services Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe mRNA Vaccine Drugs Development Services Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America mRNA Vaccine Drugs Development Services Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa mRNA Vaccine Drugs Development Services Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 mRNA Vaccine Drugs Development Services Industry Trends
- 4.2 mRNA Vaccine Drugs Development Services Industry Drivers
- 4.3 mRNA Vaccine Drugs Development Services Industry Opportunities and Challenges
- 4.4 mRNA Vaccine Drugs Development Services Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by mRNA Vaccine Drugs Development Services Revenue (2021-2026)
- 5.2 Global mRNA Vaccine Drugs Development Services Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global mRNA Vaccine Drugs Development Services Key Company Headquarters & Area Served
- 5.4 Global mRNA Vaccine Drugs Development Services Company, Product Type & Application
- 5.5 Global mRNA Vaccine Drugs Development Services Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global mRNA Vaccine Drugs Development Services Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 mRNA Vaccine Drugs Development Services Players Market Share by Revenue in 2025
- 5.6.3 2025 mRNA Vaccine Drugs Development Services Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 ReciBioPharm
- 6.1.1 ReciBioPharm Company Information
- 6.1.2 ReciBioPharm Business Overview
- 6.1.3 ReciBioPharm mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 ReciBioPharm mRNA Vaccine Drugs Development Services Product Portfolio
- 6.1.5 ReciBioPharm Recent Developments
- 6.2 Merck
- 6.2.1 Merck Company Information
- 6.2.2 Merck Business Overview
- 6.2.3 Merck mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Merck mRNA Vaccine Drugs Development Services Product Portfolio
- 6.2.5 Merck Recent Developments
- 6.3 Samsung Biologics
- 6.3.1 Samsung Biologics Company Information
- 6.3.2 Samsung Biologics Business Overview
- 6.3.3 Samsung Biologics mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Samsung Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 6.3.5 Samsung Biologics Recent Developments
- 6.4 Thermo Fisher Scientific
- 6.4.1 Thermo Fisher Scientific Company Information
- 6.4.2 Thermo Fisher Scientific Business Overview
- 6.4.3 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Product Portfolio
- 6.4.5 Thermo Fisher Scientific Recent Developments
- 6.5 Lonza
- 6.5.1 Lonza Company Information
- 6.5.2 Lonza Business Overview
- 6.5.3 Lonza mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Lonza mRNA Vaccine Drugs Development Services Product Portfolio
- 6.5.5 Lonza Recent Developments
- 6.6 Ricoh Group
- 6.6.1 Ricoh Group Company Information
- 6.6.2 Ricoh Group Business Overview
- 6.6.3 Ricoh Group mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Ricoh Group mRNA Vaccine Drugs Development Services Product Portfolio
- 6.6.5 Ricoh Group Recent Developments
- 6.7 Aldevron
- 6.7.1 Aldevron Company Information
- 6.7.2 Aldevron Business Overview
- 6.7.3 Aldevron mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Aldevron mRNA Vaccine Drugs Development Services Product Portfolio
- 6.7.5 Aldevron Recent Developments
- 6.8 Wuxi Biologics
- 6.8.1 Wuxi Biologics Company Information
- 6.8.2 Wuxi Biologics Business Overview
- 6.8.3 Wuxi Biologics mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Wuxi Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 6.8.5 Wuxi Biologics Recent Developments
- 6.9 Genscript Probio
- 6.9.1 Genscript Probio Company Information
- 6.9.2 Genscript Probio Business Overview
- 6.9.3 Genscript Probio mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Genscript Probio mRNA Vaccine Drugs Development Services Product Portfolio
- 6.9.5 Genscript Probio Recent Developments
- 6.10 Novoprotein
- 6.10.1 Novoprotein Company Information
- 6.10.2 Novoprotein Business Overview
- 6.10.3 Novoprotein mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Novoprotein mRNA Vaccine Drugs Development Services Product Portfolio
- 6.10.5 Novoprotein Recent Developments
- 6.11 Porton Advanced Solutions
- 6.11.1 Porton Advanced Solutions Company Information
- 6.11.2 Porton Advanced Solutions Business Overview
- 6.11.3 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Product Portfolio
- 6.11.5 Porton Advanced Solutions Recent Developments
- 6.12 Precision NanoSystems
- 6.12.1 Precision NanoSystems Company Information
- 6.12.2 Precision NanoSystems Business Overview
- 6.12.3 Precision NanoSystems mRNA Vaccine Drugs Development Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Precision NanoSystems mRNA Vaccine Drugs Development Services Product Portfolio
- 6.12.5 Precision NanoSystems Recent Developments
7 North America
- 7.1 North America mRNA Vaccine Drugs Development Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 7.3 North America mRNA Vaccine Drugs Development Services Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe mRNA Vaccine Drugs Development Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 8.3 Europe mRNA Vaccine Drugs Development Services Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 9.3 Asia-Pacific mRNA Vaccine Drugs Development Services Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America mRNA Vaccine Drugs Development Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 10.3 South America mRNA Vaccine Drugs Development Services Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa mRNA Vaccine Drugs Development Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 11.3 Middle East & Africa mRNA Vaccine Drugs Development Services Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst